BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 1918881)

  • 1. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization.
    Müller R; Gubernatis G; Farle M; Niehoff G; Klein H; Wittekind C; Tusch G; Lautz HU; Böker K; Stangel W
    J Hepatol; 1991 Jul; 13(1):90-6. PubMed ID: 1918881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
    Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
    Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retransplantation of patients with severe posttransplant hepatitis B in the first allograft.
    Ishitani M; McGory R; Dickson R; Caldwell S; Bickston S; McCullough C; Pruett T; Terrault N; Roberts J; Ascher N; Wright T; Lake J
    Transplantation; 1997 Aug; 64(3):410-4. PubMed ID: 9275104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
    Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration.
    Rosenau J; Kreutz T; Kujawa M; Bahr MJ; Rifai K; Hooman N; Finger A; Michel G; Nashan B; Kuse ER; Klempnauer J; Tillmann HL; Manns MP
    J Hepatol; 2007 Apr; 46(4):635-44. PubMed ID: 17316869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving experience of hepatitis B virus prophylaxis in liver transplantation.
    Honaker MR; Shokouh-Amiri MH; Vera SR; Alloway RR; Grewal HP; Hardinger KL; Kizilisik AT; Bagous T; Trofe J; Stratta RJ; Egidi MF; Gaber AO
    Transpl Infect Dis; 2002 Sep; 4(3):137-43. PubMed ID: 12421458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients.
    Stärkel P; Stoffel M; Lerut J; Horsmans Y
    Liver Transpl; 2005 Oct; 11(10):1228-34. PubMed ID: 16184571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
    Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
    Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors.
    Dodson SF; Bonham CA; Geller DA; Cacciarelli TV; Rakela J; Fung JJ
    Transplantation; 1999 Oct; 68(7):1058-61. PubMed ID: 10532552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active immunization for prevention of De novo hepatitis B virus infection after adult living donor liver transplantation with a hepatitis B core antigen-positive graft.
    Wang SH; Loh PY; Lin TL; Lin LM; Li WF; Lin YH; Lin CC; Chen CL
    Liver Transpl; 2017 Oct; 23(10):1266-1272. PubMed ID: 28691231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation.
    Ueda Y; Marusawa H; Egawa H; Okamoto S; Ogura Y; Oike F; Nishijima N; Takada Y; Uemoto S; Chiba T
    Antivir Ther; 2011; 16(4):479-87. PubMed ID: 21685535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant.
    Tchervenkov JI; Tector AJ; Barkun JS; Sherker A; Forbes CD; Elias N; Cantarovich M; Cleland P; Metrakos P; Meakins JL
    Ann Surg; 1997 Sep; 226(3):356-65; discussion 365-8. PubMed ID: 9339942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients.
    Samuel D; Bismuth A; Mathieu D; Arulnaden JL; Reynes M; Benhamou JP; Brechot C; Bismuth H
    Lancet; 1991 Apr; 337(8745):813-5. PubMed ID: 1672913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.
    Sánchez-Fueyo A; Rimola A; Grande L; Costa J; Mas A; Navasa M; Cirera I; Sánchez-Tapias JM; Rodés J
    Hepatology; 2000 Feb; 31(2):496-501. PubMed ID: 10655276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel immunoassay for the detection of hepatitis B surface 'escape' mutants and its application in liver transplant recipients.
    Ijaz S; Torre F; Tedder RS; Williams R; Naoumov NV
    J Med Virol; 2001 Mar; 63(3):210-6. PubMed ID: 11170059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis.
    Angelico M; Di Paolo D; Trinito MO; Petrolati A; Araco A; Zazza S; Lionetti R; Casciani CU; Tisone G
    Hepatology; 2002 Jan; 35(1):176-81. PubMed ID: 11786974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin.
    Terrault NA; Zhou S; Combs C; Hahn JA; Lake JR; Roberts JP; Ascher NL; Wright TL
    Hepatology; 1996 Dec; 24(6):1327-33. PubMed ID: 8938155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors.
    Roque-Afonso AM; Feray C; Samuel D; Simoneau D; Roche B; Emile JF; Gigou M; Shouval D; Dussaix E
    Gut; 2002 Jan; 50(1):95-9. PubMed ID: 11772974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose anti-hepatitis B immunoglobulin regimen as prophylaxis for hepatitis B recurrence after liver transplantation.
    Lee WC; Chou HS; Wu TH; Cheng CH; Lee CF; Wang YC; Wu TJ; Chan KM
    Transpl Infect Dis; 2019 Dec; 21(6):e13190. PubMed ID: 31587427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation.
    Karasu Z; Ozacar T; Akyildiz M; Demirbas T; Arikan C; Kobat A; Akarca U; Ersoz G; Gunsar F; Batur Y; Kilic M; Tokat Y
    Antivir Ther; 2004 Dec; 9(6):921-7. PubMed ID: 15651751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.